FindTrial
Sign In

Urinary neutrophil gelatinase ?associated lipocalin as a biomarker in predicting treatment response in patients with Hepatorenal Syndrome  - Acute kidney injury (HRS-AKI)

Urinary neutrophil gelatinase ?associated lipocalin as a biomarker in predicting therapeutic response to albumin and terlipressin in patients with Hepatorenal Syndrome  - Acute kidney injury (HRS-AKI) - nil

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/11/076443
Enrollment
100
Registered
2024-11-08
Start date
Unknown
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K746- Other and unspecified cirrhosis ofliver Health Condition 2: K746- Other and unspecified cirrhosis ofliver

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Aster Centre for Clinical Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients more than 18 years of age admitted in Aster Medcity with HRS-AKI as per International Club of Ascites

Exclusion criteria

Exclusion criteria: Patients who have Chronic kidney disease , prior solid organ transplantation, congestive heart failure in New York Hearth Association class = 3 or Obstruction of urinary tract.

Design outcomes

Primary

MeasureTime frame
complete or partial resolution of AKITimepoint: at 4 days after starting terlipressin and albumin—

Secondary

MeasureTime frame
90 days mortalityTimepoint: 90 days—

Countries

India

Contacts

Public ContactDr Eby Mathew

Aster Medcity

ebymathew6699@gmail.com9496122622

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026